Sphingolipids and hepatic steatosis

Advances in Experimental Medicine and Biology

Volumn 721, Issue , 2011, Pages 87-97

  Bikman, Benjamin T ^a   Summers, Scott A ^a,b  

^a DUKE NUS MEDICAL SCHOOL   (Singapore)

^b DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

(5' ADAMANTANE 1' YL METHOXY)PENTYL 1 1 DEOXYNOJIRIMYCIN; ADIPONECTIN; CERAMIDE GLUCOSYLTRANSFERASE; CERAMIDE GLUCOSYLTRANSFERASE INHIBITOR; DESIPRAMINE; GENZ 123346; INTERLEUKIN 1BETA; INTERLEUKIN 6; NONANOIC ACID[2 (2',3' DIHYDROBENZO[1,4]DIOXIN 6' YL) 2 HYDROXY 1 PYRROLIDIN 1 YLMETHYLETHYL]AMIDE 1 TARTARIC ACID; SERINE PALMITOYLTRANSFERASE; SPHINGOLIPID; SPHINGOMYELIN PHOSPHODIESTERASE; THERMOZYMOCIDIN; TOLL LIKE RECEPTOR 4; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ARTICLE; BIOSYNTHESIS; CYTOKINE PRODUCTION; DISEASE PREDISPOSITION; DRUG MECHANISM; DRUG TARGETING; ENZYME INHIBITION; GENE EXPRESSION; HUMAN; INFLAMMATION; LIPID ANALYSIS; LIPID LIVER LEVEL; LIPOGENESIS; LIPOLYSIS; MARKER GENE; NONALCOHOLIC FATTY LIVER; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REGULATORY MECHANISM; TNFALPHA GENE;

ADIPONECTIN; ANIMALS; CARDIOVASCULAR DISEASES; CYTOKINES; DIABETES MELLITUS, TYPE 2; DISEASE MODELS, ANIMAL; FATTY ACIDS; FATTY LIVER; GLUCOSYLTRANSFERASES; HUMANS; INFLAMMATION; LIVER; METABOLIC SYNDROME X; MICE; NEOPLASMS; OBESITY; SERINE C-PALMITOYLTRANSFERASE; SPHINGOLIPIDS; SPHINGOMYELIN PHOSPHODIESTERASE; TRIGLYCERIDES;

MUS; RODENTIA;

EID: 80053616691     PISSN: 00652598     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-1-4614-0650-1_6     Document Type: Article

References (90)

1. Grundy SM, Brewer HB Jr, Cleeman JI et al. Definition of metabolic syndrome: report ofthe National Heart, Lung and Blood Institute/American Heart Association conference on scientific issues related to definition. Arterioscler Thromb Vasc Biol 2004; 24:e13-18.
2. Economic costs ofdiabetes inthe U.S. In 2007. Diabetes Care 2008; 31:596-615.
3. Cardiovascular Disease Statistics 2009. American Heart Assocation. Available at: http://www.americanheart. org/presenter.jhtml?identifier=4478.
4. Global Strategy on Diet and Physical Activity 2009. World Health Organization. Available at: http://www. who.int/dietphysicalactivity/ publications/facts/diabetes/en/index.html.
5. Coleman RA, Lee DP. Enzymes oftriacylglycerol synthesis andtheirregulation. Prog Lipid Res 2004; 43:134-176.
6. Neuschwander-Tetri BA, Caldwell SH. Nonalcoholic steatohepatitis: summary of an AASLD Single Topic Conference. Hepatology 2003; 37:1202-1219. (Pubitemid 36538699)
7. Kim CH, Younossi ZM. Nonalcoholic fatty liver disease: a manifestation of the metabolic syndrome. Cleve Clin J Med 2008; 75:721-728.
8. FarrellGC, LarterCZ. Nonalcoholic fatty liverdisease: fromsteatosistocirrhosis. Hepatology 2006; 43:S99-S112.
9. Machado M, Marques-Vidal P, Cortez-Pinto H. Hepatic histology in obese patients undergoing bariatric surgery. J Hepatol 2006; 45:600-606. (Pubitemid 44307393)
10. Clark JM, Brancati FL, Diehl AM. The prevalence and etiology of elevated aminotransferase levels inthe United States. Am J Gastroenterol 2003; 98:960-967. (Pubitemid 36733754)
11. Turinsky J, Bayly BP, O'Sullivan DM. 1,2-Diacylglycerol and ceramide levels in rat liver and skeletal muscle in vivo. Am J Physiol 1991; 261:E620-627.
12. Holland WL, Brozinick JT, Wang LP et al. Inhibition of ceramide synthesis ameliorates glucocorticoid-, saturated-fat- and obesity-induced insulin resistance. Cell Metab 2007; 5:167-179.
13. Turinsky J, O'Sullivan DM, Bayly BP. 1,2-Diacylglycerol and ceramide levels in insulin-resistant tissues oftheratinvivo.J Biol Chem 1990;265:16880-16885.
14. Aerts JM, OttenhoffR, Powlson AS et al. Pharmacological inhibition ofglucosylceramide synthase enhances insulin sensitivity. Diabetes 2007; 56:1341-1349. (Pubitemid 46715620)
15. Yetukuri L, Katajamaa M, Medina-Gomez G et al. Bioinformatics strategies for lipidomics analysis: characterization of obesity related hepatic steatosis. BMC Syst Biol 2007; 1:12.
16. Greco D, Kotronen A, Westerbacka J et al. Gene expression in human NAFLD. Am J Physiol Gastrointest Liver Physiol 2008; 294:G1281-1287.
17. Kotronen A, Seppanen-Laakso T, Westerbacka J et al. Hepatic stearoyl-CoA desaturase (SCD)-1 activity and diacylglycerol but not ceramide concentrations are increased in the nonalcoholic human fatty liver. Diabetes 2009; 58:203-208.
18. Kolak M, Westerbacka J, Velagapudi VR et al. Adipose tissue inflammation and increased ceramide content characterize subjects with high liver fat content independent of obesity. Diabetes 2007; 56:1960-1968. (Pubitemid 47195815)
19. Summers SA. Ceramides in insulin resistance and lipotoxicity. Prog Lipid Res 2006; 45:42-72. (Pubitemid 43170804)
20. Memon RA, Holleran WM, Moser AH et al. Endotoxin and cytokines increase hepatic sphingolipid biosynthesis and produce lipoproteins enriched in ceramides and sphingomyelin. Arterioscler Thromb Vasc Biol 1998; 18:1257-1265. (Pubitemid 28376182)
21. Yang G, Badeanlou L, Bielawski J et al. Central role of ceramide biosynthesis in body weight regulation, energy metabolism and the metabolic syndrome. Am J Physiol Endocrinol Metab 2009; 297:E211-224.
22. Bijl N, Sokolovic M, Vrins C et al. Modulation of glycosphingolipid metabolism significantly improves hepatic insulin sensitivity and reverses hepatic steatosis in mice. Hepatology 2009.
23. Zhao H, Przybylska M, Wu IH et al. Inhibiting glycosphingolipid synthesis ameliorates hepatic steatosis in obese mice. Hepatology 2009; 50:85-93.
24. Mathias S, Pena LA, Kolesnick RN. Signal transduction of stress via ceramide. Biochem J 1998; 335 (Pt 3):465-480. (Pubitemid 28515396)
25. Deevska GM, Rozenova KA, Giltiay NV et al. Acid Sphingomyelinase Deficiency Prevents Diet-induced Hepatic Triacylglycerol Accumulation and Hyperglycemia in Mice. J Biol Chem 2009; 284:8359-8368.
26. Dressier KA, Mathias S, Kolesnick RN. Tumor necrosis factor-alpha activates the sphingomyelin signal transduction pathway in a cell-free system. Science 1992; 255:1715-1718.
27. Andrieu-Abadie N, Levade T. Sphingomyelin hydrolysis during apoptosis. Biochim Biophys Acta 2002; 1585:126-134. (Pubitemid 36092076)
28. Schutze S, Wiegmann K, Machleidt T et al. TNF-induced activation of NF-kappa B. Immunobiology 1995; 193:193-203.
29. Wiegmann K, Schutze S, Machleidt T et al. Functional dichotomy of neutral and acidic sphingomyelinases intumornecrosisfactorsignaling. Cell 1994;78:1005-1015. (Pubitemid 24292328)
30. Schutze S, Potthoff K, Machleidt T et al. TNF activates NF-kappa B by phosphatidylcholine-specific phospholipase C-induced "acidic" sphingomyelin breakdown. Cell 1992; 71:765-776.
31. Mathias S, Dressier KA, KolesnickRN. Characterization ofaceramide-activated protein kinase: stimulation bytumornecrosis factoralpha. Proc Natl Acad Sci USA 1991; 88:10009-10013. (Pubitemid 21915764)
32. Chatterjee S. Neutral sphingomyelinase action stimulates signal transduction of tumor necrosis factor-alpha in the synthesis of cholesteryl esters in human fibroblasts. J Biol Chem 1994; 269:879-882. (Pubitemid 24032459)
33. Liu B, Andrieu-Abadie N, Levade T et al. Glutathione regulation of neutral sphingomyelinase in tumor necrosis factor-alpha-induced cell death. J Biol Chem 1998; 273:11313-11320. (Pubitemid 28204985)
34. Segui B, Cuvillier O, Adam-Klages S, et al. Involvement of FAN in TNF-induced apoptosis. J Clin Invest 2001; 108:143-151. (Pubitemid 32634931)
35. Singh I, Pahan K, Khan M et al. Cytokine-mediated induction of ceramide production is redox-sensitive. Implications to proinflammatory cytokine-mediated apoptosis in demyelinating diseases. J Biol Chem 1998; 273:20354-20362. (Pubitemid 28377600)
36. Bettaieb A, Record M, Come MG et al. Opposite effects of tumor necrosis factor alpha on the sphingomyelin-ceramide pathway in two myeloid leukemia cell lines: role of transverse sphingomyelin distribution in the plasma membrane. Blood 1996; 88:1465-1472. (Pubitemid 26276824)
37. Vandenabeele P, DeclercqW, BeyaertRet al. Two tumour necrosis factor receptors: structure and function. Trends Cell Biol 1995; 5:392-399.
38. Tomita K, Tamiya G, Ando S et al. Tumour necrosis factor alpha signalling through activation of Kupffer cells plays an essential role in liver fibrosis of non-alcoholic steatohepatitis in mice. Gut 2006; 55:415-424. (Pubitemid 43268283)
39. Alessenko AV, Shupik MA, Bugrova AE et al. The relation between sphingomyelinase activity, lipid peroxide oxidation and NO-releasing in mice liver and brain. FEBS Lett 2005; 579:5571-5576. (Pubitemid 41455632)
40. ReinehrR, Becker S, Keitel Vet al. Bile salt-induced apoptosis involves NADPH oxidase isoform activation. Gastroenterology 2005; 129:2009-2031. (Pubitemid 41772977)
41. Day CP, James OF. Steatohepatitis: atale oftwo "hits"?. Gastroenterology 1998; 114:842-845.
42. Day CP, James OF. Hepatic steatosis: innocent bystander or guilty party?. Hepatology 1998; 27:1463-1466. (Pubitemid 28264666)
43. Day CP, Saksena S. Non-alcoholic steatohepatitis: definitions and pathogenesis. J Gastroenterol Hepatol 2002; 17(Suppl 3):S377-384. (Pubitemid 35454314)
44. Donnelly KL, Smith CI, Schwarzenberg SJ et al. Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease. J Clin Invest 2005; 115:1343-1351. (Pubitemid 40629054)
45. Utzschneider KM, Kahn SE. Review: The role of insulin resistance in nonalcoholic fatty liver disease. J Clin Endocrinol Metab 2006; 91:4753-4761. (Pubitemid 44917301)
46. Hotamisligil GS, Shargill NS, Spiegelman BM. Adipose expression of tumor necrosis factor-alpha: direct role in obesity-linked insulin resistance. Science 1993; 259:87-91. (Pubitemid 23036092)
47. Baranova A, Gowder SJ, Schlauch K et al. Gene expression of leptin, resistin and adiponectin in the white adipose tissue of obese patients with non-alcoholic fatty liver disease and insulin resistance. Obes Surg 2006; 16:1118-1125. (Pubitemid 44433145)
48. Lutchman G, Promrat K, Kleiner DE et al. Changes in serum adipokine levels during pioglitazone treatment for nonalcoholic steatohepatitis: relationship to histological improvement. Clin Gastroenterol Hepatol 2006; 4:1048-1052. (Pubitemid 44118842)
49. Li Z, Yang S, Lin H et al. Probiotics and antibodies to TNF inhibit inflammatory activity and improve nonalcoholic fatty liver disease. Hepatology 2003; 37:343-350. (Pubitemid 36152533)
50. Lin HZ, Yang SQ, Chuckaree C et al. Metformin reverses fatty liver disease in obese, leptin-deficient mice. Nat Med 2000; 6:998-1003.
51. Xu A, Wang Y, Keshaw H et al. The fat-derived hormone adiponectin alleviates alcoholic and nonalcoholic fatty liver diseases in mice. J Clin Invest 2003; 112:91-100. (Pubitemid 38056380)
52. Hui JM, Hodge A, Farrell GC et al. Beyond insulin resistance in NASH: TNF-alpha or adiponectin?. Hepatology 2004; 40:46-54. (Pubitemid 38868922)
53. Louthan MV, Barve S, McClain CJ et al. Decreased serum adiponectin: an early event in pediatric nonalcoholic fatty liver disease. J Pediatr 2005; 147:835-838. (Pubitemid 41774843)
54. Musso G, Gambino R, Biroli G et al. Hypoadiponectinemia predicts the severity of hepatic fibrosis and pancreatic Beta-cell dysfunction in nondiabetic nonobese patients with nonalcoholic steatohepatitis. Am J Gastroenterol 2005; 100:2438-2446.
55. Musso G, Gambino R, Durazzo M et al. Adipokines in NASH: postprandial lipid metabolism as a link between adiponectin and liver disease. Hepatology 2005; 42:1175-1183. (Pubitemid 43112685)
56. Kaser S, Moschen A, Cayon A et al. Adiponectin and its receptors in non-alcoholic steatohepatitis. Gut 2005; 54:117-121. (Pubitemid 40007229)
57. Lemoine M, Ratziu V, Kim M et al. Serum adipokine levels predictive of liver injury in non-alcoholic fatty liver disease. Liver Int 2009.
58. Jarrar MH, Baranova A, Collantes R et al. Adipokines and cytokines in non-alcoholic fatty liver disease. Aliment Pharmacol Ther 2008; 27:412-421.
59. Feldstein AE, Werneburg NW, Canbay A et al. Free fatty acids promote hepatic lipotoxicity by stimulating TNF-alpha expression via a lysosomal pathway. Hepatology 2004; 40:185-194. (Pubitemid 38868937)
60. Crespo J et al. Gene expression of tumor necrosis factor alpha and TNF-receptors, p55 and p75, in nonalcoholic steatohepatitis patients. Hepatology 2001; 34:1158-1163. (Pubitemid 33096588)
61. Abiru S et al. Serum cytokine and soluble cytokine receptor levels in patients with non-alcoholic steatohepatitis. Liver Int 2006; 26:39-45.
62. Hannun YA, Bell RM. The sphingomyelin cycle: a prototypic sphingolipid signaling pathway. Adv Lipid Res 1993; 25:27-41.
63. Kolesnick R, Golde DW. The sphingomyelin pathway in tumor necrosis factor and interleukin-1 signaling. Cell 1994; 77:325-328. (Pubitemid 24145193)
64. Messmer TO, Wang E, Stevens VL et al. Sphingolipid biosynthesis by rat liver cells: effects of serine, fatty acids and lipoproteins. J Nutr 1989; 119:534-538. (Pubitemid 19116766)
65. Gill J M, Sattar N. Ceramides: Anewplayerintheinflammation- insulinresistanceparadigm?Diabetologia2009.
66. Samad F, Hester KD, Yang G et al. Altered adipose and plasma sphingolipid metabolism in obesity: a potential mechanism for cardiovascular and metabolic risk. Diabetes 2006; 55:2579-2587. (Pubitemid 44871159)
67. Shah C, Yang G, Lee I et al. Protection from high fat diet-induced increase in ceramide in mice lacking plasminogen activator inhibitor 1. J Biol Chem 2008; 283:13538-13548.
68. de Mello VD, Lankinen M, Schwab U et al. Link between plasma ceramides, inflammation and insulin resistance: association with serum IL-6 concentration in patients with coronary heart disease. Diabetologia 2009; 52:2612-2615.
69. de Mello VD, Lankinen M, Schwab U et al. Linkbetween plasma ceramides, inflammation and insulinresistance: association with serum IL-6 concentration in patients with coronary heart disease. Diabetologia 2009.
70. Li Z, Soloski MJ, Diehl AM. Dietary factors alter hepatic innate immune system in mice with nonalcoholic fatty liver disease. Hepatology 2005; 42:880-885. (Pubitemid 41401126)
71. Bouwens L, Baekeland M, De Zanger R et al. Quantitation, tissue distribution and proliferation kinetics ofKupffer cells in normal rat liver. Hepatology 1986; 6:718-722. (Pubitemid 16038195)
72. Racanelli V, Rehermann B. The liver as an immunological organ. Hepatology 2006; 43:S54-62.
73. Bouwens L, Knook DL, Wisse E. Local proliferation and extrahepatic recruitment of liver macrophages (Kupffer cells) in partial-body irradiated rats. J Leukoc Biol 1986; 39:687-697. (Pubitemid 16082832)
74. Kawai T, Akira S. Innate immune recognition of viral infection. Nat Immunol 2006; 7:131-137. (Pubitemid 43135878)
75. Szabo G, Dolganiuc A, Mandrekar P. Pattern recognition receptors: a contemporary view on liver diseases. Hepatology 2006; 44:287-298. (Pubitemid 44214866)
76. Fessler MB, Rudel LL, Brown JM. Toll-like receptor signaling links dietary fatty acids to the metabolic syndrome. Curr Opin Lipidol 2009; 20:379-385.
77. Seki E, Brenner DA. Toll-like receptors and adaptor molecules in liver disease: update. Hepatology 2008; 48:322-335. (Pubitemid 351975556)
78. Treffkorn L, Scheibe R, Maruyama T et al. PGE2 exerts its effect on the LPS-induced release of TNF-alpha, ET-1, IL-1alpha, IL-6 and IL-10 via the EP2 and EP4 receptor in rat liver macrophages. Prostaglandins Other Lipid Mediat 2004; 74:113-123. (Pubitemid 39360224)
79. Szabo G, Velayudham A, Romics L Jr et al. Modulation ofnon-alcoholic steatohepatitis by pattern recognition receptors in mice: the role of toll-like receptors 2 and 4. Alcohol Clin Exp Res 2005; 29:140S-145S. (Pubitemid 43194341)
80. Seki E et al. Lipopolysaccharide-induced IL-18 secretion from murine Kupffer cells independently of myeloid differentiation factor 88 that is critically involved in induction of production of IL-12 and IL-1beta. J Immunol 2001; 166:2651-2657. (Pubitemid 32173504)
81. Su GL. Lipopolysaccharides in liver injury: molecular mechanisms ofKupffer cell activation. Am J Physiol Gastrointest Liver Physiol 2002; 283:G256-265. (Pubitemid 34791290)
82. Nakao A, Taki S, Yasui M et al. The fate of intravenously injected endotoxin in normal rats and in rats withliverfailure. Hepatology 1994; 19:1251-1256. (Pubitemid 24134249)
83. Memon RA, Holleran WM, Uchida Y et al. Regulation of sphingolipid and glycosphingolipid metabolism in extrahepatic tissues by endotoxin. J Lipid Res 2001; 42:452-459. (Pubitemid 32270070)
84. Peng Y, Rideout D, Rakita S et al. Downregulation ofAdiponectin/AdipoR2 is Associated with Steatohepatitis in Obese Mice. J Gastrointest Surg 2009.
85. Ma H, Gomez V, Lu L et al. Expression of adiponectin and its receptors in livers of morbidly obese patients with non-alcoholic fatty liver disease. J Gastroenterol Hepatol 2009; 24:233-237.
86. Yamauchi T, Kamon J, Waki H et al. The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity. Nat Med 2001; 7:941-946. (Pubitemid 32756432)
87. Stefan N, Machicao F, Staiger H et al. Polymorphisms in the gene encoding adiponectin receptor 1 are associated with insulin resistance and high liver fat. Diabetologia 2005; 48:2282-2291. (Pubitemid 41618919)
88. Villa NY, Kupchak BR, Garitaonandia I et al. Sphingolipids function as downstream effectors of a fungal PAQR. Mol Pharmacol 2009; 75:866-875.
89. Blazquez C, Geelen MJ, Velasco G et al. The AMP-activated protein kinase prevents ceramide synthesis de novo and apoptosis in astrocytes. FEBS Lett 2001; 489:149-153. (Pubitemid 32126399)
90. Holland WL, Scherer PE. PAQRs: a counteracting force to ceramides?. Mol Pharmacol 2009; 75:740-743.